J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Balance Sheet

Balance Sheet Decomposition
Jafron Biomedical Co Ltd

Current Assets 3.2B
Cash & Short-Term Investments 2.7B
Receivables 120m
Other Current Assets 348.6m
Non-Current Assets 2.2B
Long-Term Investments 116.1m
PP&E 1.9B
Intangibles 110.8m
Other Non-Current Assets 122.6m
Current Liabilities 1B
Accounts Payable 133.1m
Accrued Liabilities 116.9m
Short-Term Debt 338.8m
Other Current Liabilities 420.1m
Non-Current Liabilities 1.4B
Long-Term Debt 1.2B
Other Non-Current Liabilities 159.6m

Balance Sheet
Jafron Biomedical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
233
288
760
1 062
1 076
1 272
1 575
2 314
2 541
2 742
Cash
0
0
0
0
0
0
0
2 314
2 526
2 742
Cash Equivalents
233
287
760
1 062
1 076
1 272
1 575
0
14
0
Short-Term Investments
0
0
0
0
0
0
0
150
0
0
Total Receivables
37
57
82
109
143
171
232
327
267
105
Accounts Receivables
37
52
75
106
127
158
167
269
222
75
Other Receivables
0
5
6
3
16
13
65
57
46
30
Inventory
35
39
51
45
61
92
121
197
349
385
Other Current Assets
6
16
107
15
25
24
59
68
136
81
Total Current Assets
311
400
999
1 231
1 305
1 560
1 987
3 056
3 293
3 312
PP&E Net
201
260
275
416
555
717
963
1 434
1 815
1 876
PP&E Gross
201
260
275
416
555
717
963
1 434
1 815
1 876
Accumulated Depreciation
12
20
31
47
67
93
125
172
238
316
Intangible Assets
17
18
17
31
47
48
90
101
100
100
Goodwill
7
7
7
18
44
44
44
44
38
12
Long-Term Investments
0
0
0
0
91
101
99
111
69
116
Other Long-Term Assets
3
4
2
7
11
25
34
64
97
127
Other Assets
7
7
7
18
44
44
44
44
38
12
Total Assets
539
N/A
689
+28%
1 300
+89%
1 702
+31%
2 052
+21%
2 495
+22%
3 217
+29%
4 810
+50%
5 413
+13%
5 543
+2%
Liabilities
Accounts Payable
10
28
20
26
30
33
50
61
102
93
Accrued Liabilities
20
29
28
50
72
81
108
165
142
112
Short-Term Debt
0
0
0
0
0
0
0
0
343
304
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
3
5
20
Other Current Liabilities
24
32
36
194
177
149
173
157
125
301
Total Current Liabilities
54
89
84
270
279
263
331
386
717
829
Long-Term Debt
0
0
0
0
0
0
0
914
954
1 392
Deferred Income Tax
0
0
0
0
0
1
1
1
0
17
Minority Interest
0
0
0
0
23
28
27
25
16
5
Other Liabilities
33
36
32
41
51
61
52
125
152
152
Total Liabilities
87
N/A
125
+44%
116
-7%
311
+169%
354
+14%
352
0%
410
+16%
1 451
+254%
1 839
+27%
2 396
+30%
Equity
Common Stock
370
370
412
417
417
419
799
805
808
808
Retained Earnings
82
194
396
597
853
1 173
1 670
2 336
2 507
2 408
Additional Paid In Capital
0
0
376
515
535
606
348
618
678
694
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
4
27
0
Treasury Stock
0
0
0
138
107
60
14
524
510
881
Other Equity
0
0
0
0
0
5
3
119
119
119
Total Equity
452
N/A
564
+25%
1 184
+110%
1 391
+17%
1 699
+22%
2 143
+26%
2 807
+31%
3 359
+20%
3 574
+6%
3 147
-12%
Total Liabilities & Equity
539
N/A
689
+28%
1 300
+89%
1 702
+31%
2 052
+21%
2 495
+22%
3 217
+29%
4 810
+50%
5 413
+13%
5 543
+2%
Shares Outstanding
Common Shares Outstanding
703
703
783
783
785
791
797
795
793
776

See Also

Discover More